Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Daiichi Sankyo
I-Mab Biopharma US Limited
Merus B.V.
Pfizer
Xijing Hospital
Amgen
M.D. Anderson Cancer Center
Guangzhou University of Traditional Chinese Medicine
Fundación Sociedad Española de Oncologia Médica
MacroGenics
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)